Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFUZOSIN HYDROCHLORIDE vs MIGLITOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Reversible competitive inhibitor of alpha-glucosidase in the intestinal brush border; delays glucose absorption and lowers postprandial hyperglycemia.
Treatment of benign prostatic hyperplasia (BPH),Off-label: Management of ureteral stones (medical expulsive therapy)
Type 2 diabetes mellitus as monotherapy or in combination with sulfonylureas, metformin, or insulin when diet and exercise do not provide adequate glycemic control
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
25 mg orally three times daily with the first bite of each main meal; may increase to 50 mg three times daily after 4-8 weeks, maximum 100 mg three times daily.
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Plasma elimination half-life ≈ 2 hours; clinical effect (alpha-glucosidase inhibition) persists longer due to enzyme binding; half-life increases in renal impairment (creatinine clearance < 25 m L/min).
Extensively metabolized in the liver, primarily via CYP3A4, to inactive metabolites.
Not metabolized; excreted unchanged in feces (via enzymatic breakdown in gut lumen) and urine (minor).
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Primarily excreted unchanged in urine (≈ 65%) via glomerular filtration; remainder recovered as metabolites in urine (25%) and feces (5%); total recovery in urine and feces ≈ 95% within 24 hours.
82-90% bound to human serum albumin and alpha-1-acid glycoprotein.
Negligible (< 4%), primarily bound to albumin.
Approximately 2.5-3.2 L/kg; indicates extensive extravascular distribution.
Approximately 0.18 L/kg; distributes mainly in extracellular fluid with limited tissue penetration.
Oral immediate-release: 64% (first-pass metabolism); extended-release: 49% relative to immediate-release.
Low and variable oral bioavailability: approximately 50% (range 35–65%) due to incomplete absorption and intestinal metabolism; dose proportional for doses up to 100 mg.
For Cr Cl 30-49 m L/min: 10 mg once daily; for Cr Cl <30 m L/min: contraindicated.
GFR <25 m L/min/1.73m2: contraindicated. No adjustment needed for GFR ≥25 m L/min/1.73m2.
Child-Pugh A: 10 mg once daily; Child-Pugh B or C: contraindicated.
No dose adjustment required for hepatic impairment; not studied in Child-Pugh C. Use with caution in severe hepatic disease.
Not established; safety and efficacy in children <18 years have not been studied.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment recommended; monitor for orthostatic hypotension and dizziness.
No specific dose adjustment, but monitor renal function; elderly may have age-related decline in renal function. Use lowest effective dose.
None.
None.
Risk of hypotension, especially orthostatic hypotension, particularly with dose initiation or increase,May cause syncope, especially in patients with predisposing factors (e.g., hypovolemia, concurrent antihypertensives),Use with caution in patients with hepatic impairment,Intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients on or previously treated with alpha-1 blockers,Should not be used in combination with other alpha-1 blockers
Hypoglycemia risk when used with insulin or sulfonylureas,Hepatotoxicity (rare, monitor liver enzymes),Gastrointestinal side effects (flatulence, diarrhea, abdominal pain) due to undigested carbohydrates in colon
Hypersensitivity to alfuzosin hydrochloride or any component of the formulation,Concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir),Moderate to severe hepatic impairment (Child-Pugh B or C)
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Intestinal obstruction or predisposition to obstruction,Chronic intestinal diseases associated with malabsorption,Hypersensitivity to miglitol
Take with food to reduce the risk of hypotension. Avoid grapefruit juice as it may increase alfuzosin levels. High-fat meals may alter absorption; consistency in meal timing is advised.
Carbohydrates in the meal may cause increased flatulence and diarrhea. Sucrose and table sugar are not effective for treating hypoglycemia; use pure glucose. Avoid excessive simple carbohydrates if tolerated.
Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregnant women. First trimester: no evidence of fetal harm from animal data. Second and third trimesters: potential risk of maternal hypotension affecting uteroplacental perfusion; limited human data available.
No adequate well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at doses up to 150 mg/kg in rats and 75 mg/kg in rabbits. Risk cannot be ruled out; use only if clearly needed.
It is unknown if alfuzosin is excreted in human breast milk. The M/P ratio has not been determined. Caution is advised due to potential for adverse effects in nursing infants, including hypotension. Alternative agents with more safety data are preferred during breastfeeding.
No data on presence in human milk. M/P ratio unknown. Consider benefit of breastfeeding versus potential risk to infant.
No specific dose adjustments are recommended due to lack of pharmacokinetic data in pregnancy. However, increased plasma volume during pregnancy may reduce drug levels; clinical effect should be monitored. Use lowest effective dose if necessary, and avoid in patients with severe hypotension or hypovolemia.
No pharmacokinetic studies in pregnancy; dosing adjustments not established. Monitor glycemic control closely and adjust as needed per clinical response.
Alfuzosin is a selective alpha-1 adrenergic antagonist used for benign prostatic hyperplasia (BPH). It has fewer cardiovascular side effects than other alpha-blockers due to its higher affinity for alpha-1a receptors in the prostate. Do not use in patients with moderate to severe hepatic impairment. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Use with caution in patients with prolonged QT interval or on QT-prolonging drugs. Administer after the same meal each day to reduce first-dose syncope.
Miglitol is an alpha-glucosidase inhibitor that delays carbohydrate absorption. It is not effective for type 1 diabetes. Monitor liver enzymes; cases of hepatitis have been reported. Do not use in patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction. Hypoglycemia must be treated with oral glucose (dextrose), not sucrose because sucrase is inhibited. Take with the first bite of each main meal.
Take this medication immediately after a meal at the same time each day.,Avoid situations that may cause dizziness or fainting, especially after the first dose or when increasing dose.,Do not crush, chew, or open the tablet; swallow whole.,Do not drive or operate heavy machinery until you know how the medication affects you.,Inform your doctor if you experience severe dizziness, fainting, or irregular heartbeat.,Avoid alcohol, which can increase dizziness and blood pressure-lowering effects.,Do not take with other alpha-blockers or medications for erectile dysfunction without consulting your doctor.
Take miglitol three times daily at the start of each main meal (with the first bite).,If you miss a dose, skip it if the meal is already finished; do not double the dose.,Common side effects include flatulence, diarrhea, and abdominal pain; these may decrease over time.,If hypoglycemia occurs, use glucose tablets or gel; table sugar (sucrose) will not work.,Inform your doctor if you have a history of kidney disease, inflammatory bowel disease, or intestinal obstruction.
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, can enhance the antihypertensive effect of Benidipine, a dihydropyridine calcium channel blocker. This occurs through additive vasodilation, potentially leading to excessive reductions in blood pressure. Clinically, patients may experience orthostatic hypotension, dizziness, or syncope, particularly during initial co-administration or dose adjustments."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, may potentiate the hypotensive effects of lamotrigine, an anticonvulsant. This interaction is primarily due to additive vasodilation, leading to an increased risk of orthostatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or with dose adjustments. Patients, especially those with cardiovascular comorbidities, should be monitored for blood pressure changes and symptoms of hypotension."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, reduces peripheral vascular resistance by blocking alpha-1 receptors on vascular smooth muscle. Pentolinium, a ganglionic blocker, inhibits sympathetic outflow by competitively blocking nicotinic acetylcholine receptors at autonomic ganglia, leading to pronounced hypotension. When combined, their additive vasodilatory effects can cause excessive hypotension, increased risk of syncope, dizziness, and potential cardiovascular collapse, especially during initial therapy or dose escalation."
"Miglitol, an alpha-glucosidase inhibitor, delays carbohydrate digestion and absorption, reducing postprandial hyperglycemia. Stanozolol, an anabolic steroid, can increase insulin sensitivity and enhance glucose utilization, potentially leading to additive hypoglycemic effects. Concurrent use may result in unexpectedly low blood glucose levels, especially in diabetic patients on insulin or sulfonylureas."
"Miglitol, an alpha-glucosidase inhibitor, delays carbohydrate absorption and reduces postprandial hyperglycemia. Levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may enhance insulin sensitivity or alter glucose metabolism, potentially increasing the hypoglycemic effect when combined with miglitol. This interaction could result in additive blood glucose lowering and an elevated risk of hypoglycemic episodes, particularly in diabetic patients."
"Saquinavir, a protease inhibitor used in HIV therapy, may decrease the therapeutic efficacy of miglitol, an alpha-glucosidase inhibitor for type 2 diabetes, by potentially increasing gastrointestinal motility or altering gut enzyme activity. This interaction can lead to reduced miglitol absorption and diminished postprandial glycemic control, increasing the risk of hyperglycemia in diabetic patients. Clinical outcomes include elevated blood glucose levels and potential loss of diabetes management."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFUZOSIN HYDROCHLORIDE vs MIGLITOL, answered by our medical review team.
ALFUZOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.. MIGLITOL is a Alpha-Glucosidase Inhibitor that works by Reversible competitive inhibitor of alpha-glucosidase in the intestinal brush border; delays glucose absorption and lowers postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFUZOSIN HYDROCHLORIDE and MIGLITOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFUZOSIN HYDROCHLORIDE is: 10 mg orally once daily immediately after the same meal each day. Extended-release tablet.. The standard adult dose of MIGLITOL is: 25 mg orally three times daily with the first bite of each main meal; may increase to 50 mg three times daily after 4-8 weeks, maximum 100 mg three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFUZOSIN HYDROCHLORIDE and MIGLITOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFUZOSIN HYDROCHLORIDE is classified as Category C. Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregn. MIGLITOL is classified as Category A/B. No adequate well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at doses up to 150 mg/kg in rats and 75 mg/kg in rabbits. Risk cannot be ruled . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.